Tivozanib + Enzalutamide in Adv Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to National Comprehensive Cancer Network
Related studies linked through entity extraction aliases.
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Tivozanib for Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
- Status
- WITHDRAWN
- Phase
- PHASE1
Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation
- Status
- UNKNOWN
- Phase
- PHASE2
Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
- Status
- COMPLETED
- Phase
- PHASE1
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
- Status
- TERMINATED
- Phase
- PHASE2
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
- Status
- COMPLETED
- Phase
- PHASE2
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
- Status
- TERMINATED
- Phase
- PHASE2
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Dose Escalation Study of Pazopanib Plus TH-302
- Status
- COMPLETED
- Phase
- PHASE1